BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 15950315)

  • 41. Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma.
    Kerr KM; MacKenzie SJ; Ramasami S; Murray GI; Fyfe N; Chapman AD; Nicolson MC; King G
    J Pathol; 2004 Jun; 203(2):638-44. PubMed ID: 15141378
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.
    Pan Q; Pao W; Ladanyi M
    J Mol Diagn; 2005 Aug; 7(3):396-403. PubMed ID: 16049312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
    Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
    J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype.
    Marchetti A; Buttitta F; Pellegrini S; Chella A; Bertacca G; Filardo A; Tognoni V; Ferreli F; Signorini E; Angeletti CA; Bevilacqua G
    J Pathol; 1996 Jul; 179(3):254-9. PubMed ID: 8774479
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EGFRvIII mutation in lung cancer correlates with increased EGFR copy number.
    Sasaki H; Kawano O; Endo K; Yukiue H; Yano M; Fujii Y
    Oncol Rep; 2007 Feb; 17(2):319-23. PubMed ID: 17203167
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.
    Sartori G; Cavazza A; Sgambato A; Marchioni A; Barbieri F; Longo L; Bavieri M; Murer B; Meschiari E; Tamberi S; Cadioli A; Luppi F; Migaldi M; Rossi G
    Am J Clin Pathol; 2009 Apr; 131(4):478-89. PubMed ID: 19289583
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.
    Gow CH; Chien CR; Chang YL; Chiu YH; Kuo SH; Shih JY; Chang YC; Yu CJ; Yang CH; Yang PC
    Clin Cancer Res; 2008 Jan; 14(1):162-8. PubMed ID: 18172267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma.
    Kitamura H; Kameda Y; Nakamura N; Nakatani Y; Inayama Y; Iida M; Noda K; Ogawa N; Shibagaki T; Kanisawa M
    Am J Pathol; 1995 Apr; 146(4):876-87. PubMed ID: 7717455
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung.
    Awaya H; Takeshima Y; Yamasaki M; Inai K
    Am J Clin Pathol; 2004 May; 121(5):644-53. PubMed ID: 15151204
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features.
    Erman M; Grunenwald D; Penault-Llorca F; Grenier J; Besse B; Validire P; Morat L; Girard P; Le Chevalier T; Sabatier L; Soria JC
    Lung Cancer; 2005 Mar; 47(3):315-23. PubMed ID: 15713515
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma.
    Matsumoto S; Iwakawa R; Kohno T; Suzuki K; Matsuno Y; Yamamoto S; Noguchi M; Shimizu E; Yokota J
    Int J Cancer; 2006 May; 118(10):2498-504. PubMed ID: 16353158
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monoclonality of atypical adenomatous hyperplasia of the lung.
    Niho S; Yokose T; Suzuki K; Kodama T; Nishiwaki Y; Mukai K
    Am J Pathol; 1999 Jan; 154(1):249-54. PubMed ID: 9916939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma.
    Koga T; Hashimoto S; Sugio K; Yoshino I; Mojtahedzadeh S; Matsuo Y; Yonemitsu Y; Sugimachi K; Sueishi K
    Clin Cancer Res; 2001 Jun; 7(6):1730-8. PubMed ID: 11410513
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib.
    Pastorino U; Calabrò E; Tamborini E; Marchianò A; Orsenigo M; Fabbri A; Sozzi G; Novello S; De Marinis F
    J Thorac Oncol; 2009 Feb; 4(2):266-7. PubMed ID: 19179908
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The significance of associated pre-invasive lesions in patients resected for primary lung neoplasms.
    Ruffini E; Bongiovanni M; Cavallo A; Filosso PL; Giobbe R; Mancuso M; Molinatti M; Oliaro A
    Eur J Cardiothorac Surg; 2004 Jul; 26(1):165-72. PubMed ID: 15200997
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lung adenocarcinoma with bronchioloalveolar carcinoma component is frequently associated with foci of high-grade atypical adenomatous hyperplasia.
    Koga T; Hashimoto S; Sugio K; Yonemitsu Y; Nakashima Y; Yoshino I; Matsuo Y; Mojtahedzadeh S; Sugimachi K; Sueishi K
    Am J Clin Pathol; 2002 Mar; 117(3):464-70. PubMed ID: 11888087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer.
    Hsieh RK; Lim KH; Kuo HT; Tzen CY; Huang MJ
    Chest; 2005 Jul; 128(1):317-21. PubMed ID: 16002952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is high-grade adenomatous hyperplasia an early bronchioloalveolar adenocarcinoma?
    Ullmann R; Bongiovanni M; Halbwedl I; Fraire AE; Cagle PT; Mori M; Papotti M; Popper HH
    J Pathol; 2003 Nov; 201(3):371-6. PubMed ID: 14595748
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung.
    Cooper CA; Carby FA; Bubb VJ; Lamb D; Kerr KM; Wyllie AH
    J Pathol; 1997 Apr; 181(4):401-4. PubMed ID: 9196437
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer.
    Sekine I; Takami S; Guang SG; Yokose T; Kodama T; Nishiwaki Y; Kinoshita M; Matsumoto H; Ogura T; Nagai K
    Oncol Rep; 1998; 5(2):351-4. PubMed ID: 9468555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.